

Week of October 5-11, 2015

## DEPARTMENT OF PSYCHIATRY & BEHAVIORAL NEUROSCIENCES



### Weekly Newsletter

#### In this Issue

Save the Date  
Lectures, Meetings & Grand Rounds  
AHA Heart Walk  
Mental Health, Guns & Violence  
Brain Health Fair  
Contact List  
Current Research

#### Save the Date!

10/30	Mental Health, Guns, & Violence
10/30	Farewell for Dr. de Erausquin
11/3	Brain Health Fair
11/7	AHA Annual Heart Walk
11/18	Thanksgiving Potluck Luncheon
12/12	Department Holiday Party at Dr. Currier's House

### Resident Lectures

Thursday, October 8

PGY 1-4 & Child & Adolescent Psychiatry Residents  
Please see the weekly didactic notice emails from the Education Office for scheduled topics and presenters

### Third Year Medical Students

Friday, October 9

8:00 - 9:00 AM	Child Case Discussion - Dr. Saundra Stock
9:00 - 10:00 AM	Child Case Discussion - Dr. Saundra Stock
10:00 - 11:00 AM	TBI/Dementia Case Discussion - Dr. Sean Phillips
11:00 AM - 12:00 PM	TBI/Dementia Case Discussion - Dr. Sean Phillips

### Grand Rounds

Thursday, October 8, 12:00 - 1:00pm

"Adult ADHD: Evaluation and Treatment" presented by Adria Savino, M.D.  
USF Psychiatry Building, Second Floor Conference Room #232  
3515 E. Fletcher Ave, Tampa, FL 33613

### CONGRATULATIONS!

#### 2015 Best Doctor in America Recipients

Dr. Alvaro, Dr. Barnett, Dr. Bengston  
Dr. Glenn Catalano, Dr. Marie Catalano, Dr. Cavitt  
Dr. Gootam, Dr. Huska, Dr. Murphy  
Dr. Phillips, Dr. Roth, Dr. Sanchez  
Dr. Shaw, Dr. Stewart, Dr. Stock, Dr. Winston

Dr. Tan received a \$224,250 NIH Grant

### AHA Heart Walk

Be sure to check your email for updates about our "Psych Will Hike" team for this year's American Heart Association annual Heart Walk. There is just over one month left to sign up. Friends and family are welcome. You can sign up and/or donate [here](#).

### Mental Health, Guns, & Violence

Friday, October 30, 9:00am-noon | USF Gibbons Alumni Center-Traditions Hall  
Join us for a free colloquium on mental health, guns, and violence.

Featured presenters include: Jeffrey Swanson, PhD, Professor, Psychiatry & Behavioral Sciences, Duke University School of Medicine;  
Alan Lizotte, PhD, Professor, School of Criminal Justice, University at Albany, State University of New York; JD Withrow, USF Chief of Police; Jane Castor, Former Tampa Chief of Police; Linda MacKinnon, President and CEO, Central Florida Behavioral Health Network, Inc.

Event is open to the public. This event is sponsored by the USF Departments of Criminology and Mental Health Law and Policy, along with the Louis de la Parte Florida Mental Health Institute.

### Brain Health Fair

Tuesday, November 3, 8:30am-3:30pm | 4001 E. Fletcher Ave, Tampa, FL 33613

Please join us for a free health expo offering memory screenings,\* various exhibits and services such as blood pressure checks, balance screenings, medication reviews, and hearing screenings. Free vehicle safety checks for senior drivers will be provided.

To register for the event please visit [Eventbrite.com](#) or call 813-396-0659

\*For a memory screening appointment, please pre-register by visiting [alz.health.usf.edu](#)

Memory checks provided by the USF Health Bryd Alzheimer's Institute and the USF Department of Psychiatry's Memory Disorders Clinic. Medication reviews provided by a pharmacist from the USF College of Pharmacy. Hearing screenings provided by the USF Department of Communication Sciences & Disorders.

### Contact List

Please check your emails for a contact list for frequently requested services sent by Doreen Shockley. This list is meant to serve as an overview of who to contact for various services. Please contact Jose Alvarez for additions, changes, or suggestions to this list.

### Happy Birthday!

Melvina Harris-Sousa (10/6)

Pat Crump (10/7)

Nicole Thompson (10/10)

### Current Research

#### Now Enrolling – Mild Alzheimer's Disease

This is a double-blind, placebo-controlled study to test the safety and effectiveness of an anti-amyloid antibody administered subcutaneously as a disease-modifying treatment in patients age 50 - 90 with mild AD. Stable dose of approved medications for AD will be permitted at study entry. Patients will undergo brain MRI exams for monitoring safety and response to study treatment. They will also undergo safety and cognitive testing. Patients must have a person with whom they are regular contact, who can accompany them to study visits. Please call Kathy at (813) 974-7006 to make a referral.

*Principal Investigator: Jean Fils, MD*

#### Now Enrolling – Major Depressive Disorder Study for Adolescent Patients

This is a double-blind, placebo-and active -controlled study to test the safety and efficacy of Levomilnacipran ER treatment in adolescent patients age 12-17 with Major Depressive Disorder. In addition, the study is designed to obtain pharmacokinetics (PK) data to guide dose selection for future pediatric studies of levomilnacipran. Patients could be enrolled into the 10mg, 20mg, 40mg or placebo group. Patients will also undergo safety and severity of symptoms assessments. Please call Colleen at (813) 974-9104 to make a referral.

*Principal Investigator: Daniel Fallon, MD*

#### SPRITES: A Non-Interventional, Longitudinal, Cohort Study to Evaluate the Effects of long-term Sertraline Treatment in Children and Adolescents (IRB # 12-0382)

Has your child received a new sertraline prescription OR recently started psychotherapy? Then your child may be eligible for **SPRITES**. The purpose of the study is to evaluate the risks and benefits of up to 3 years treatment with sertraline on cognition (thinking), emotional and physical development, and pubertal (sexual) maturation in children between the ages of 6 to 16 years. There are 8 visits over 3 years. Compensation per visit is available. Please call 727-767-8230 for more information.

*Principal Investigator: Tanya Murphy, MD*

#### Immune characterization of a control cohort for identifying potential immunological biomarkers and psychosocial correlates in pediatric patients presenting with neuropsychiatric disorders through comparative analysis (IRB # 00022667)

The purpose of this study is to obtain biological samples, including blood, urine, stool, throat, nasal, and buccal (cheek) swabs from **healthy youth** to compare to samples collected from patients with neuropsychiatric disorders including obsessive-compulsive disorder (OCD), tic disorders, and autism spectrum disorders (ASD). Our aim is to identify factors that can be used to help understand the causes of these pediatric neuropsychiatric disorders and aid in developing better diagnostic tools and treatments. Additionally, we hope to understand how immune-related events, such as infections, contribute to these disorders and how they impact clinical presentations including symptom course and severity, and response to therapeutic intervention. The study participation is one visit of approximately 2 hours in length. During the visit, the child and parent will complete interviews and questionnaires. We will collect biological samples, including blood, urine, and throat/nasal/cheek swabs. Numbing cream is available. A complete physical and neurological exam will be given to the child. There is the option of providing a stool sample which is collected at home. There is no cost to the family. Compensation of \$50 for the visit is available.

#### USF Rothman Center Tourette Syndrome Studies

Additionally, the USF Rothman Center is seeking children and adolescents with a diagnosis of **Tourette Syndrome** who are willing to participate in a pharmaceutical study. There are two studies which may be of interest. Study visits are at no charge. Compensation is available for the study visits. Please contact the study team for specific information:

##### T-Force Study; Neurocrine Biological Sciences

We invite boys and girls aged 6 to 18 who have a diagnosis of **Tourette syndrome** to see if they qualify for the T-Force Study. The primary purpose of this research study is to determine the safety and tolerability of an investigational medication for Tourette syndrome. Each child will be evaluated to determine his or her eligibility to participate in the research study. Each participant who qualifies will receive the investigational medication, study-related medical exams, and laboratory tests at no cost. As some of the medical appointments can be lengthy, many forms of entertainment will become available to your child at his or her study visits. Compensation for time and travel may also be available. Please call 727-767-8230 for more information.

*Principal Investigator: Tanya Murphy, MD*

##### Psyadon Pharmaceuticals

Your child is invited to take part in a new clinical research program sponsored by Psyadon Pharmaceuticals which is using PSYRX101, an experimental synthetic drug, where the active ingredient is Ecopipam that acts as to stop the actions of one of these neurotransmitters and to help relieve the symptoms of **Tourette Syndrome**. The primary purpose of this research study is to determine the safety and tolerability of this investigational medication for Tourette syndrome in children between the ages of 7 and 17 years. Each potential subject will be evaluated to determine his or her eligibility to participate in the research study. Each participant who qualifies will receive the investigational medication, study-related medical exams, and laboratory tests at no cost. Compensation is available. Please call 727-767-8230 for more information.

*Principal Investigator: Tanya Murphy, MD*

#### 2/3 Treatment of Anxiety in Autism Spectrum Disorder (IRB # 00064328)

The researchers are currently investigating how a personalized cognitive behavioral therapy (CBT) program for children with **Autism Spectrum Disorder** (ASD) compares to a standard practice CBT program in helping children overcome their anxiety. All children between the ages of 8 and 13 years who qualify for the study will receive 16 sessions of CBT treatment. If your child qualifies for the study, there is a 45% chance s/he will receive personalized CBT for children with ASD, 45% chance s/he will receive standard practice CBT and a 10% chance s/her will receive normal treatment (with the option of receiving your choice of cognitive behavioral therapy at the end of the study. No matter which group your child is in s/he would participate in three additional visits to the clinic to complete study assessments. All assessments and therapy sessions are provided free of charge. Please call 727-767-8230 for more information.

*Principal Investigator: Eric Storch, PhD*

#### Modular Treatment for Preschooler and Young Children with Anxiety (IRB # 00022196)

This research is being done to test how well a certain type of mostly parent-focused cognitive behavioral therapy (CBT) works for pre-school aged children with anxiety. Study participants are between the age of 3 to 7 years of age, and their parent needs to be present during the assessments and therapy. Study participation is approximately 10 months. There is no cost for the assessments and therapy. Some compensation is available. Please call 727-767-8230 for more information.

*Principal Investigator: Adam Lewin, PhD*

#### Stepped Care Cognitive Behavioral Therapy for Pediatric Obsessive-Compulsive Disorder (IRB # 13-0620)

This research is being done to determine how well we can help kids with obsessive-compulsive disorder (OCD) using therapy that requires less clinic visits. We are testing a Stepped-Care Cognitive Behavioral Therapy (Stepped-Care CBT) approach in which kids receive a full course of parent-led, therapist guided treatment for OCD. The goal is to see if therapy can be done in fewer visits to our clinic. Children receiving Stepped-Care CBT will start with Step One, which includes three therapy sessions over six weeks. Those who do not get better in Step One will "STEP UP" to Step Two which involves coming in to meet with a CBT for the remaining sessions. We will compare youth receiving Stepped-Care CBT to youth receiving standard CBT in our clinic through this study. Children with obsessive-compulsive disorder between the ages of 8 and 17 years old and their parent may join.

Please call 727-767-8230 for more information.

*Principal Investigator: Adam Lewin, PhD*

For more information on current open studies or to refer a patient, please call Kathy 813-974-7006 or Colleen 813-974-9104